Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience

Emicizumab is a humanized recombinant bispecific antibody, bridging together activated factor IX (FIXa) and factor X (FX), thus mimicking the activity of FVIII in vivo. Emicizumab is designed for long-term prophylaxis in patients with severe hemophilia A with and without inhibitors. This approach provides constant protection, with significant reduction in bleeding rate and improved quality of life. However, protection provided by emicizumab is not absolute, and clotting factor concentrates (FVIII, rFVIIa, aPCC) may be necessary for post-traumatic bleeding or surgery, with a potential thrombotic risk or difficulty in preventing bleeding. Real world evidence is still scanty, especially for managing major surgery. In this study, 75 surgeries were managed in 28 patients (27 major procedures in 15 patients and 48 minor procedures in 20 patients. In 17 patients without inhibitors, 30 minor surgeries were carried out by using FVIII in 5, with only a bleeding event, which was successfully treated with FVIII concentrate. Six major surgeries were uneventfully performed with FVIII concentrate. Eleven PWHA and high-titer inhibitors underwent 39 surgical procedures (18 minor and 21 major surgeries). Minor surgeries were mostly performed without prophylaxis with rFVIIa, with only a single bleeding complication. All 21 major surgeries were covered with a homogeneous protocol using rFVIIa. In four instances, bleeding complications occurred, treated with rFVIIa. Of them, a single patient only failed to respond and died because of an uncontrollable bleeding from a large ruptured retroperitoneal pseudotumor. Surgery in patients with emicizumab can be safely carried out with the use of appropriate replacement therapy protocols.

[1]  V. Jiménez‐Yuste,et al.  Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies , 2022, Blood advances.

[2]  B. Nolan,et al.  Port removal in patients receiving emicizumab prophylaxis: A single centre experience and review of the literature , 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

[3]  V. Jiménez‐Yuste,et al.  Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery , 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  G. Kenet,et al.  Emicizumab prophylaxis: Prospective longitudinal real‐world follow‐up and monitoring , 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  J. Oldenburg,et al.  Long-term outcomes with emicizumab prophylaxis for hemophilia A with/without FVIII inhibitors from the HAVEN 1-4 studies. , 2020, Blood.

[6]  M. Lewandowska,et al.  Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real‐world experience from a large comprehensive treatment centre in the US , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[7]  M. Franchini,et al.  Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  E. Santagostino,et al.  WFH Guidelines for the Management of Hemophilia, 3rd edition , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  R. Butler,et al.  Real‐world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  E. Santagostino,et al.  Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. , 2020, Blood transfusion = Trasfusione del sangue.

[11]  J. Oldenburg,et al.  A multicenter, open-label, phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. , 2019, Blood.

[12]  P. Kuebler,et al.  Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program , 2019, Journal of thrombosis and haemostasis : JTH.

[13]  J. Oldenburg,et al.  Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A , 2019, Thrombosis and Haemostasis.

[14]  C. Hermans,et al.  Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. , 2019, The Lancet. Haematology.

[15]  J. Oldenburg,et al.  Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors , 2018, The New England journal of medicine.

[16]  O. Christophe,et al.  Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? , 2017, Blood.

[17]  J. Oldenburg,et al.  Emicizumab Prophylaxis in Hemophilia A with Inhibitors , 2017, The New England journal of medicine.

[18]  Tetsuji Sato,et al.  Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A. , 2016, The New England journal of medicine.

[19]  A. Savic,et al.  Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[20]  D Bergqvist,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients , 2010, Journal of thrombosis and haemostasis : JTH.

[21]  F. Girolami,et al.  Identification of seven novel mutations of F8C by DHPLC , 2002, Human mutation.